GlassScriptPhysician profile
Stephen T Steiner
NPI 1023102951
$1,858.76
in general payments reported to CMS, 2019-2025
20 companies · $428 in 2025
The $428 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.83 · 2021: $217 · 2022: $395 · 2023: $442 · 2024: $305 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,175.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $683.80 | 2021-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $279.04 | 2021-2025 | Stelara, Tremfya |
| Conmed Corporation | $125.00 | 2023 | Conmed Biliary |
| E.R. Squibb & Sons, L.L.C. | $124.64 | 2022 | |
| Madrigal Pharmaceuticals | $123.46 | 2024 | Rezdiffra |
| Gilead Sciences, INC. | $102.00 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.30 | 2021-2025 | Gattex, Entyvio |
| Cook Medical LLC | $53.45 | 2021-2023 | Hemospray |
| Braintree Laboratories, INC. | $53.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.97 | 2023-2025 | Xifaxan |
| Lilly USA, LLC | $33.88 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $32.18 | 2024 | Voquezna |
| Qol Medical, LLC | $30.50 | 2019-2023 | Sucraid |
| Organon LLC | $25.46 | 2024 | |
| Ironwood Pharmaceuticals, INC | $15.03 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $14.91 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $13.71 | 2022 | |
| Medtronic, INC. | $13.14 | 2024 | Nexpowder |
| Daiichi Sankyo INC. | $12.99 | 2023 | Injectafer |
| Micro-Tech Endoscopy USA, INC. | $11.98 | 2024 | Cold Snares |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Steiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.